3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
12
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
4
Neoplasm Metastasis
3
Urethral Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Carcinoma
1
Interventions
pembrolizumab
7
padeliporfin
5
Nivolumab
4
Everolimus
4
Sunitinib
3
Sorafenib
3
Mitomycin
3
fludarabine
2
epothilone B
2
durvalumab
2
cabozantinib
2
Ipilimumab
2
Cyclophosphamide
2
Cisplatin
2
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
volociximab
1
vinflunine
1
sipuleucel-T
1
sargramostim
1
pemigatinib
1
palladium-bacteriopheophorbide
1
palbociclib
1
obinutuzumab
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
fludarabine phosphate
1
enzalutamide
1
belzutifan
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
vinflunine
×
Genitourinary
×
Clear all
NCT01529411
2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
86 enrolled